BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 07, 2015
 |  BioCentury  |  Finance

Eyes in Europe

Why Bristol-Myers Squibb invested in LSP's latest European life sciences fund

Bristol-Myers Squibb Co. (NYSE:BMY) is banking on LSP's expertise in early stage European investing to give the pharma access to emerging technologies and companies on the Continent.

For its first-ever investment in a European healthcare fund, the pharma put an undisclosed amount into LSP 5. While LSP was not actively looking for new strategic investors, Joachim Rothe told BioCentury the firm is happy to play a role as BMS's European scout.

"They felt that they would want to find ways of having eyes and ears in Europe. And going forward, we will play that role for them,"...

Read the full 485 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >